Cargando…

Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis

OBJECTIVE: To determine the risk factors associated with lower respiratory tract infections (LRTI) related hospitalizations in preterm infants receiving palivizumab throughout the high season for respiratory syncytial virus (RSV) infection. METHODS: Premature infants who were commenced on palivizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oncel, Mehmet Yekta, Arayici, Sema, Simsek, Gulsum Kadioglu, Calisici, Erhan, Erdeve, Omer, Uras, Nurdan, Oguz, Serife Suna, Dilmen, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025129/ https://www.ncbi.nlm.nih.gov/pubmed/24910750

Ejemplares similares

Can Base Excess be Used for Prediction to Early Diagnosis of Neonatal Sepsis in Preterm Newborns?
por: Arayici, Sema, et al.
Publicado: (2019)

Toxoplasmosis-Associated Hemophagocytosis in a Preterm Newborn
por: Arayıcı, Sema, et al.
Publicado: (2014)

A Neonate with Subcutaneous Fat Necrosis after Passive Cooling: Does Polycythemia Have an Effect?
por: Calisici, Erhan, et al.
Publicado: (2013)

Evaluation of prolonged pain in preterm infants with pneumothorax using heart rate variability analysis and EDIN (Échelle Douleur Inconfort Nouveau-Né, neonatal pain and discomfort scale) scores
por: Buyuktiryaki, Mehmet, et al.
Publicado: (2018)

Hydrops Fetalis due to Kell Alloimmunization: A Perinatal Approach to a Rare Case
por: Akdağ, Arzu, et al.
Publicado: (2012)

Bedside Repair of Omphalocele
por: Yilmaz, Yavuz, et al.
Publicado: (2012)

A novel association between cerebral sinovenous thrombosis and nonketotic hyperglycinemia in a neonate
por: Yurttutan, Sadık, et al.
Publicado: (2015)

The Effect of Surgery Time on Prognosis in Newborns with Meningomyelocele
por: Oncel, Mehmet Yekta, et al.
Publicado: (2012)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

Effects of cord blood vitamin D levels on the risk of neonatal sepsis in premature infants
por: Say, Birgul, et al.
Publicado: (2017)

Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit
por: Dizdar, E.A., et al.
Publicado: (2010)

Comparison of Bilevel Volume Guarantee and Pressure-Regulated Volume Control Modes in Preterm Infants
por: Işık, Şehribanu, et al.
Publicado: (2023)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

The Effects of Antenatal Steroid Treatment on Preterm Infants’ Early Laboratory Analysis
por: Simsek, Gulsum Kadioglu, et al.
Publicado: (2020)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009
por: Chang, Seung Gu, et al.
Publicado: (2010)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2014)

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
por: Resch, B., et al.
Publicado: (2017)

The associations between caffeine treatment and common preterm morbidities: a retrospective cohort analysis
por: Yavanoglu Atay, Funda, et al.
Publicado: (2023)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
por: Coletta, Elio, et al.
Publicado: (2010)

A multicenter study on epidemiological and clinical characteristics of 125 newborns born to women infected with COVID-19 by Turkish Neonatal Society
por: Oncel, Mehmet Yekta, et al.
Publicado: (2020)

Correction to: A multicenter study on epidemiological and clinical characteristics of 125 newborns born to women infected with COVID-19 by Turkish Neonatal Society
por: Oncel, Mehmet Yekta, et al.
Publicado: (2020)

Congenital Laryngeal Cyst: A Rare Cause of Polyhydramnios
por: Aksoy, Hatice Tatar, et al.
Publicado: (2013)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

Turkish Neonatal Society guideline on the management of patent ductus arteriosus in preterm infants
por: Köksal, Nilgün, et al.
Publicado: (2018)

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies
por: Bonati, Poliana Castro de Resende, et al.
Publicado: (2022)

Can High Average Oxygen Saturation be a Risk Factor for Necrotizing Enterocolitis in VLBW Infants?
por: Gokce, Ismail Kursad, et al.
Publicado: (2019)

Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
por: Paes, Bosco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_djt4kaikjmh373vn02kep0srio